ADR database

ADR DATABASE

References:

FDA - MEDWATCH (april 1997)
Reviewed: 09/1997

Deferoxamine (antidote)
Warnings

High doses of deferoxamine and concomitant low ferritin levels have been associated with growth retardation. After reduction of deferoxamine dose, growth velocity may partially resume to pretreatment rates.

References:

FDA - MEDWATCH (april 1997) Reviewed: 09/1997

Warnings

Acute respiratory distress syndrome has been described following treatment with excessively high intravenous doses of deferoxamine.

ADR DATABASE

References:

FDA - MEDWATCH (april 1997)
Reviewed: 09/1997

Deferoxamine (antidote)

Warnings

High doses of deferoxamine and concomitant low ferritin levels have been associated with growth retardation. After reduction of deferoxamine dose, growth velocity may partially resume to pretreatment rates.

References:

FDA - MEDWATCH (april 1997) Reviewed: 09/1997

Warnings

Acute respiratory distress syndrome has been described following treatment with excessively high intravenous doses of deferoxamine.

Return to the index of the database

The latest updates on ADRs are presented in the

News
on Adverse Drug Reactions

News
on Adverse Drug Reactions

Return to main page

References: FDA - MEDWATCH (april 1997) Reviewed: 09/1997	Deferoxamine (antidote) Warnings High doses of deferoxamine and concomitant low ferritin levels have been associated with growth retardation. After reduction of deferoxamine dose, growth velocity may partially resume to pretreatment rates.
References: FDA - MEDWATCH (april 1997) Reviewed: 09/1997	Warnings Acute respiratory distress syndrome has been described following treatment with excessively high intravenous doses of deferoxamine.

ADR DATABASE

References: FDA - MEDWATCH (april 1997) Reviewed: 09/1997

Deferoxamine (antidote)

Warnings

High doses of deferoxamine and concomitant low ferritin levels have been associated with growth retardation. After reduction of deferoxamine dose, growth velocity may partially resume to pretreatment rates.

References: FDA - MEDWATCH (april 1997) Reviewed: 09/1997

Warnings

Acute respiratory distress syndrome has been described following treatment with excessively high intravenous doses of deferoxamine.

Return to the index of the database The latest updates on ADRs are presented in the Newson Adverse Drug Reactions

Newson Adverse Drug Reactions

References:

FDA - MEDWATCH (april 1997)
Reviewed: 09/1997

References:

FDA - MEDWATCH (april 1997) Reviewed: 09/1997

Return to the index of the database

The latest updates on ADRs are presented in the

News
on Adverse Drug Reactions

News
on Adverse Drug Reactions